文献速递乳腺癌放疗放疗物理与技术

平均心脏剂量是乳腺癌放疗中左心室和冠状动脉暴露的相关替代参数吗:基于个体化确定辐射剂量的剂量学评估(BACCARAT研究)

Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study).
PubMed 文献 · Radiat Oncol · 2019-02-07

基于BACCARAT前瞻性研究,对89例左侧和15例右侧乳腺癌患者分析3D适形放疗下心脏及亚结构剂量分布。左侧患者平均心脏剂量(MHD)为2.9±1.5 Gy,左前降支(LAD)平均剂量为15.7±3.1 Gy,LAD/MHD比值约5;MHD与亚结构平均剂量的决定系数R²中低(LAD的R²=0.45),MHD<3 Gy的左侧患者中56%仍可接受LAD剂量高于40 Gy(V40>0)。结论认为MHD不足以可靠预测左心室和冠状动脉的个体剂量,尤其LAD。

要点

  • 左侧乳腺癌患者MHD为2.9±1.5 Gy,LAD平均剂量为15.7±3.1 Gy,LAD/MHD比值约5。
  • MHD与各亚结构平均剂量的相关系数均显著,但R²中低,LAD的R²=0.45。
  • MHD<3 Gy的左侧患者中56%仍可接受LAD剂量高于40 Gy(V40>0)。

核心结论

  • MHD不足以可靠预测左心室和冠状动脉的个体患者剂量,尤其LAD。
  • 为精确研究放疗所致心脏毒性,需考虑这些心脏亚结构内的剂量分布而非仅MHD。

研究设计与样本

  • BACCARAT前瞻性研究,纳入2015至2017年接受3D适形放疗的单侧乳腺癌患者,随访2年并重复心脏影像检查。
  • 所有患者放疗前接受冠状动脉计算机断层扫描血管造影(CCTA),将计划CT与CCTA图像配准以在计划CT上勾画冠状动脉。
  • 利用治疗计划生成的3D剂量矩阵和勾画的冠状动脉轮廓,生成全心脏及左心室、左主干、左前降支、左回旋支和右冠状动脉的剂量分布。
  • 对89例左侧乳腺癌患者和15例右侧乳腺癌患者进行物理剂量描述性分析,Dmean为体积加权平均剂量。

主要发现

  • 左侧乳腺癌患者MHD=2.9±1.5 Gy,LAD平均剂量=15.7±3.1 Gy;右侧乳腺癌患者MHD=0.5±0.1 Gy,右冠状动脉平均剂量=1.2±0.4 Gy。
  • 左侧乳腺癌患者LAD平均剂量/MHD比值约为5。
  • MHD与勾画亚结构的平均剂量之间的Pearson相关系数均具有统计学显著性。
  • 所有亚结构的决定系数R²提示由MHD可预测的亚结构平均剂量方差比例为中低,尤其LAD的R²=0.45。
  • MHD<3 Gy的左侧乳腺癌患者中,56%仍可接受LAD剂量高于40 Gy(V40>0)。

关键数值与推荐

  • 左侧乳腺癌患者MHD=2.9±1.5 Gy,LAD平均剂量=15.7±3.1 Gy。
  • 右侧乳腺癌患者MHD=0.5±0.1 Gy,右冠状动脉平均剂量=1.2±0.4 Gy。
  • 左侧乳腺癌患者LAD平均剂量/MHD比值约5。
  • MHD与LAD平均剂量的决定系数R²=0.45。
  • MHD<3 Gy的左侧乳腺癌患者中56%可接受LAD剂量高于40 Gy(V40>0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intra-individual heterogeneity of cardiac exposure is an issue in breast cancer (BC) radiotherapy that was poorly considered in previous cardiotoxicity studies mainly based on mean heart dose (MHD). This dosimetric study analyzes the distribution of individually-determined radiation doses to the heart and its substructures including coronary arteries and evaluate whether MHD is a relevant surrogate parameter of dose for these substructures. METHODS: Data were collected from the BACCARAT prospective study that included left or right unilateral BC patients treated with 3D-Conformal Radiotherapy (RT) between 2015 and 2017 and followed-up for 2 years with repeated cardiac imaging examinations. A coronary computed tomography angiography (CCTA) was performed before RT for all patients. Registration of the planning CT and CCTA images allowed delineation of the coronary arteries on the planning CT images. Using the 3D dose matrix generated during treatment planning and the added coronary contours, dose distributions were generated for whole heart and the following substructures: left ventricle (LV), left main coronary artery (LMCA), left anterior descending artery (LAD), left circumflex artery (LCX) and right coronary artery (RCA). A descriptive analysis of the physical doses in Gray (Gy) was performed, Dmean was the volume-weighted mean dose. RESULTS: Dose distributions were generated for 89 left-sided BC patients (MHD = 2.9 ± 1.5 Gy, Dmean_LAD = 15.7 ± 3.1 Gy) and 15 right-sided BC patients (MHD = 0.5 ± 0.1 Gy; Dmean_RCA = 1.2 ± 0.4 Gy). For left-sided BC patients, the ratio Dmean_LAD/MHD was around 5. Pearson correlation coefficients between MHD and Dmean for delineated substructures were all statistically significant. However, for all substructures, the coefficient of determination R2 indicated that the proportion of the variance in Dmean of the substructure predictable from MHD was moderate to low (in particular R2 = 0.45 for LAD). Among left-sided BC patients with MHD < 3Gy, 56% of patients could nevertheless receive LAD doses above 40Gy (V40 > 0). CONCLUSION: Our study illustrates that MHD is not enough to predict with confidence individual patient dose to the LV and coronary arteries, in particular the LAD. For precise radiotherapy-induced cardiotoxicity studies it would be necessary to consider the distribution of doses within these cardiac substructures rather than just the MHD. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02605512 , Registered 6 November 2015 - Retrospectively registered.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jacob S, Camilleri J, Derreumaux S, et al. Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study). Radiat Oncol. 2019. PMID: 30732640. doi:10.1186/s13014-019-1234-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。